The CCG has a duty to ensure that all its dealings are conducted to the highest standards of integrity and probity. Our hospitality and gifts policy sets out the procedure that staff of the CCG must follow when receiving gifts and/or hospitality. This page is maintained by the Corporate Governance Manager
This register is updated only when there are new entries to be published.
COVID-19: there is known to be an increase in the offer of gifts and donations at unprecedented levels during COVID-19. This show of support from the nation is greatly appreciated. However, all gifts and donations must be properly managed and used for the purpose for which they were intended. CCG staff have been reminded as to the process and thresholds for declaration, which is otherwise unchanged from what is stated in the above published policy. Gifts and donations will therefore appear on the above register in line with CCG policy as and when they are declared.
Primary Care Rebate Schemes
What are Primary Care Rebate Schemes (PCRS)?
These are contractual arrangements offered by pharmaceutical companies, or third party companies, which offer retrospective financial rebates to the CCG on GP prescribing expenditure for particular branded medicine(s).
Some schemes may attract a rebate for both the CCG and primary care member practices, whereas others attract a rebate only for the CCG. Conflicts of interest may arise where there is a clear financial pecuniary benefit for CCG clinical directors who are also partners in member practices, and so will be managed accordingly.
Pharmaceutical Industry Scheme Governance Board (PISGB) and PrescQIPP
Governance arrangements include delegated authority by the CCG Executive Committee to accept participation in schemes where they are assessed by the Pharmaceutical Industry Scheme Governance Board (PISGB) as appropriate through meeting pre-determined assessment criteria (“grey” rated schemes). The role of the PISGRB is only to provide an independent assessment of any particular scheme. The process for assessment through PISGB is managed by PrescQIPP, an NHS funded not for profit organisation (https://www.prescqipp.info/). The criterion for assessment of schemes by the Pharmaceutical Industry Scheme Governance Board (PISGB) is:
- The therapeutic initiative has a place in clinical practice
- The arrangements for the scheme are simple and easy for the NHS to implement
- There is a transparent, sensible plan for payment and tracking
- The governance on what the scheme is, and is not going to be used for is robust
- There is a plan for ongoing review
The outcome of assessment against criteria will result in recommendation to commissioners that the scheme is deemed:
- Grey – Scheme considered: No significant reservations
- Amber – Scheme considered: Not fully appropriate
- Red – Scheme considered: Not appropriate
CCG delegated authority
The delegated authority is currently held by the CCG Medicines Optimisation Lead and Associate Director of Medicines Management as CCG voting members of the Integrated Care Partnership (ICP) Medicines Optimisation Board. At this board there are no voting rights for practice partner member GPs who may be conflicted in decisions on participation where there is a pecuniary benefit, and which takes the role of managing the local formulary (a list of drugs approved for prescription to patients).
Escalation to the CCG Executive Committee for decision on acceptance to participate
This will occur where assessed by the Pharmaceutical Industry Scheme Governance Board (PISGB) as rated amber of red. Were decision to participate deemed to involve a direct and material conflict of interest for a voting member, a decision to participate may be further escalated to the CCG Governing Body.
Reporting arrangements: scheme participation is to be reported at least once annually to CCG Executive Committee, CCG Governing Body and CCG Audit Committee, separate to any individual decision escalations.
Scheme participation – 2020/21
The CCG is participating in the following rebate schemes (2020/21), which offer rebate only to the CCG and not to primary care member practices. They are payable quarterly unless otherwise stated.
|Drug||Condition||Company||Start||End||Notice||Date CCG committee approval (where escalated)|
|Aventis pharma (Sanofi)||01/07/19
|30/06/21||One month CCG
|25/07/2019 (failed on initial financial assessment, approved Executive Committee)|
|Insulin Apidra||30/06/20 *|
|Insulin Lantus (unsulin glargine)||30/06/21||n/a|
|Insulin Lispro||30/06/20 *||n/a|
|Edoxaban||Anticoagulant||The Free Radical Network||22/05/18||31/12/22||Either party 12 months||n/a|
|Resource Thicken Up Contract (RTUC)||Dietetics||Nestle UK Ltd||29/04/19||28/04/21||Three months CCG||n/a|
|Clenil Modulite||Asthma||Chiesi Ltd||01/07/19||30/06/21||Six months CCG||n/a|
|AirFLuSal||Asthma||Novartis Pharma||01/04/21||31/03/22||Six months CCG||n/a|
|Physeptone; methadone hydrochloride 1mg||Pain
|Ethypharm||No start date shown – contract signed 20/1/20||2 years||3 months’ notice CCG/12mth supplier||n/a|
|Xaggitin XL; Methylphenidate prolonged release tablets||ADHD||31/12/21|
|XARELTO; Rivaroxaban||Clotting||Bayer||20/01/20||31/12/21||Either party one month|
|Primary Care Dressings||Convatec Limited||01/02/20||31/01/22||1 month notice CCG/24mths supplier|